The Celiac Care Gap Begins After Diagnosis
Portable gluten detection tools are not a substitute for standard care. Used carefully, they may help clinicians support patients when hidden gluten exposure remains a problem.
Takeda acquires PvP Biologics for $330M following Phase I celiac disease study results
Takeda plans to submit data from the study for later presentation and initiate a Phase IIb trial of the drug, TAK-062, in celiac disease patients. In October, it in-licensed another celiac disease drug, COUR Pharmaceuticals' CNP-101/TAK-101.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Takeda backs new celiac spin-out PvP Biologics
Washington University spin-out PvP Biologics has bypassed traditional seed financing, jumping straight into a development agreement with Takeda Pharmaceuticals to further its investigational therapy for celiac disease.
Gluten-free diets: Actually necessary or did the trend get to your head?
Gluten-free diets are thriving among Americans who either really think they have an intolerance, even celiac disease, or perhaps just think it’s healthier in general. But how does a legitimate intolerance turn into a booming health trend? There are whole aisles in specialty grocery stores dedicated to gluten-free products, which would imply that many people […]
Helping those with celiac disease tolerate gluten: ImmusanT raises $12M
So far, the only treatment available for celiac disease is a gluten-free diet. Cambridge biotech ImmusanT aims to reprogram the immune system of a person with celiac disease so they can tolerate gluten. ImmusanT just raised $12 million in a Series B round for its Nexvax2 drug and diagnostic for celiac disease. The dollars will go […]
First drug discovery startup emerges from GSK-Avalon deal to take on celiac disease
The $495 million innovation collaboration between GlaxoSmithKline and early-stage investor Avalon Ventures has produced its first fruits in the form of a company initially focused on treating celiac disease. Sitari Pharmaceuticals launched today with a $10 million Series A from Avalon and GSK and technology from Stanford University. It’s still in the early discovery phase, […]
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!